Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
MLTX
Stock Latest News
The Fly
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi
2d ago
MLTX
Premium
Company Announcements
Moonlake Immunotherapeutics Advances Psoriatic Arthritis Treatment with Sonelokimab Study
3d ago
MLTX
Premium
Company Announcements
MoonLake Immunotherapeutics Advances with Promising Sonelokimab Study in Adolescents
3d ago
MLTX
Premium
Company Announcements
Moonlake Immunotherapeutics Advances in Hidradenitis Suppurativa Treatment with Sonelokimab Study
3d ago
MLTX
Premium
Company Announcements
MoonLake’s Promising Phase 3 Study on Sonelokimab for Psoriatic Arthritis
3d ago
MLTX
Premium
Class Action
MoonLake Faces Legal Storm Over SLK Drug Claims
8d ago
MLTX
Premium
The Fly
MoonLake Immunotherapeutics price target lowered to $25 from $104 at Oppenheimer
24d ago
MLTX
Premium
The Fly
Unusually active option classes on open October 3rd
28d ago
CAN
EYE
Premium
The Fly
MoonLake Immunotherapeutics downgraded to Neutral from Buy at H.C. Wainwright
29d ago
MLTX
Premium
The Fly
MoonLake Immunotherapeutics downgraded to Neutral from Buy at Goldman Sachs
1M ago
MLTX
Premium
The Fly
Unusually active option classes on open September 30th
1M ago
CAN
GLW
Premium
The Fly
MoonLake Immunotherapeutics price target lowered to $20 from $66 at Needham
1M ago
MLTX
Premium
The Fly
Guggenheim cuts MoonLake Immunotherapeutics price target, removes as Best Idea
1M ago
MLTX
Premium
Ratings
Hold Rating for MoonLake Immunotherapeutics Amid Clinical and Financial Challenges
1M ago
MLTX
Premium
The Fly
MoonLake Immunotherapeutics downgraded to Neutral from Buy at Citi
1M ago
MLTX
Premium
The Fly
MoonLake Immunotherapeutics double-downgraded to Underperform at Wolfe Research
1M ago
MLTX
Premium
The Fly
MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research
1M ago
MLTX
Premium
The Fly
MoonLake price target lowered to $12 from $108 at Clear Street
1M ago
MLTX
Premium
The Fly
Jefferies downgrades MoonLake Immunotherapeutics after VELA results
1M ago
MLTX
Premium
The Fly
MoonLake Immunotherapeutics downgraded to Hold from Buy at Jefferies
1M ago
MLTX
Premium
Market News
Morning Wrap-Up: Monday’s Biggest Stock Market Stories!
1M ago
BP
EA
Premium
The Fly
Leerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake news
1M ago
MLTX
ORKA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
